Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas - Scorecard - MDSpire
Advertisement
Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas
Clinical Scorecard: Evaluation of Sentinel Lymph Node Biopsy Outcomes in Colon Cancer Considering Population Anthropometrics and Body Composition Assessment Methods
At a Glance
Category
Detail
Condition
Colon cancer (CC) with focus on lymph node metastasis status
Key Mechanisms
Sentinel lymph node biopsy (SLNB) detects first nodal station metastasis; advanced histopathological techniques (IHC, RT-PCR) improve staging accuracy
Target Population
Patients with histopathologically confirmed, resectable colon cancer, aged >18 years, ASA I-III, no prior colon/mesocolon surgery
Care Setting
Surgical oncology and general surgery clinics performing open colon cancer resections with SLNB
Key Highlights
Lymph node metastasis significantly decreases 5-year survival in colorectal cancer from 70–90% to 40–60%.
SLNB allows detailed examination of first draining lymph nodes, potentially upstaging nodal status beyond standard H&E staining.
Anthropometric factors like BMI and intra-abdominal obesity may affect SLNB detection rates and false negative results.
Guideline-Based Recommendations
Diagnosis
Perform SLNB during standard en block colon cancer resection to assess sentinel lymph nodes.
Use serial tissue slicing and immunohistochemical staining (IHC) for micrometastases detection in SLNs.
Classify SLNs as positive if H&E positive or micrometastases (0.2–2 mm) detected by IHC; isolated tumor cells (<0.2 mm) considered negative.
Management
Standard treatment remains en block resection of tumor with margin of healthy tissue and mesocolon.
Consider adjuvant chemotherapy for patients with regional lymph node involvement to improve survival.
Identify 'high risk' stage II patients potentially benefiting from adjuvant therapy based on SLNB findings.
Monitoring & Follow-up
Calculate detection rate, sensitivity, accuracy, upstaging, false positive rate, and negative predictive value to assess SLNB quality.
Monitor patient anthropometric parameters (BMI, Roher’s index, lean body weight) as potential factors influencing SLNB efficacy.
Risks
Intra-abdominal obesity may impair identification of dyed lymph nodes, increasing false negative SLNB results.
False negatives in SLNB can lead to understaging and missed indications for adjuvant therapy.
Patient & Prescribing Data
103 patients with colon cancer undergoing SLNB; median age 65 years; both sexes included
SLNB combined with advanced histopathology may improve nodal staging accuracy, guiding adjuvant therapy decisions; anthropometric measures may predict SLNB success
Clinical Best Practices
Ensure SLNB performed by surgeons with adequate experience (minimum 10 procedures).
Administer Patent Blue dye subserosally in 2–4 ml divided into four injections for lymphatic mapping.
Observe pigmentation of lymph vessels and nodes within 5–10 minutes to identify sentinel nodes.
Mark SLNs with sutures for targeted histopathological analysis.
Use multisectioning and IHC staining on SLNs negative by H&E to detect micrometastases.
Exclude patients with suspicious lymph nodes, advanced tumors, distant metastases, or emergency surgery indications from SLNB studies.
